The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Https://www.dailymail.co.uk/health/article-13178459/Daily-pills-answer-incurable-cancer-patients-aggressive-disease-tumors-stop-growing.html
Am sure our chk1 could be tried with this???
Thanks HbD. Not long in from a nightshift.
Regards
Morning SOG - History page shows updates
https://clinicaltrials.gov/study/NCT02797964?intr=CHK1%20SRA737&rank=1&tab=history
Interesting look from latest developments from Acrivon pipeline.
https://acrivon.com/pipeline/
Not new info as from 2019 a year before the withdrawal of the for sale sign of 737 and patent protection obtained by SO.
From T Sen.
Given that anti–PD-L1/anti–PD-1 drugs have recently been approved as monotherapy and in combination with chemotherapy for the treatment of SCLC, and that the SRA737 + low dose gemcitabine regimen is currently in clinical trials for SCLC and other malignancies, our preclinical data provide a strong rational for combining this regimen with inhibitors of the PD-L1/PD-1 pathway.
As cancer treatments develop it is becoming very clear of the importance of CHK1 inhibition, most especially in combo therapy.
I have had thoughts on the likelihood that it may have been an intention to scupper other companies from using these combo therapies due to patent protection. Clearly much research has been done in this field of treatment for treating cancers yet very few have progressed to later stage trials.
Prexasertib taken on by Acrivon.
Prexasertib as far as l know not been trialled in anyway with a PD-1 inhibitor.
Regards
And a pleasurable read, thanks to all and good to see C79 back in the mix!!
By the way, usual MM shenanigans late this afternoon - the 2 number 28k trades were not both sells but in fact a Bed & ISA by the missus!
Enjoy the weekend as we hopefully "bound" on to some good news - fingers crossed!
GLA
Https://www.degruyter.com/document/doi/10.1515/hsz-2023-0111/html
"The triple drug combination-induced cytotoxicity was partially enhanced by siRNA-mediated Mcl-1 silencing. Our findings suggest that targeting Chk1 may be used as an efficient strategy for sensitization of prostate cancer cells to killing action of platinum-based chemotherapeutic drugs and TRAIL."
ATB
- Beer-Garden Time, (Coat on of course)
Come on US Private Biotech put our CHK1 in the limelight and let’s start to have some of our $80m milestone payments. Our Mk Cap is such a joke right now….
Clinical-stage CHK1 inhibitors /
https://www.oncologypipeline.com/apexonco/boundless-enthusiasm-chk1
Hi C79 - I'd also pondered the 'what if' of someone getting 737 to intentionally hinder progress but going by the known terms of the deal, the licensee will be handing over additional fees made up of up to US$1.0 million cash and 500,000 shares in the Licensee Company upon the sooner of 12 months following the signing of the Licensing Agreement, or the event of the Licensee Company achieving certain commercial and material financing objectives.
So we'd assume the BoD will have to name whichever company we'll have 135,000 shares in as and when the time comes. That should allow us to look at their own pipeline to gauge their direction and intentions.
Maybe Boundless Bio pre-empted their listing when they added that clause into the agreement (assuming it's them as their CSO was also CSO at Sierra!)
Morning gents, you are right, it is only a tiny little doubt - that's the conspiracy theorist in me!
I trust CCT245737 will break cover in the near future and all will be revealed; as you say onwards and upwards.
ATVB
I think we can be reasonably certain that 737 was only "sold on" with the stipulation it would not be shelved after the debacle with SO ... LH&K Mafuta
Very odd that we have no idea who has taken on 245737.
Chk1i certainly not dead. 2 months now and no update to a licence that is nigh identical to the old Pronai Therapeutics licence.
It is along the lines of an ex member of SO wanted a continuation of the license from CPF.
Possibility of a new company set up for the development of 737 as mentioned private company.
Somebody keeping it all very hush hush for which there must be a reason.
Am certain the old agreement the licensee was required to update the CPF every 3 months.
Doing a lot if digging around but nothing concrete. Would a company set a new company up for the purpose if CHK1 development? If so for what purpose?
Regards and onwards and upwards for 1801.
Boundless Bio bumps IPO market back to life after sleepy few weeks:
https://www.fiercebiotech.com/biotech/boundless-bio-bumps-ipo-market-back-life-after-sleepy-few-weeks
FORM S-1 - REGISTRATION STATEMENT with SEC
https://www.sec.gov/Archives/edgar/data/1782303/000119312524060708/d493037ds1.htm
Boundless Bio Announces Multiple Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2024:
https://finance.yahoo.com/news/boundless-bio-announces-multiple-upcoming-213000930.html
And don't forget Cambridge, UK based Sentinel Oncology with their CHK1i:
2020 - Sentinel collaboration with PharmaEngine for Pep-07 / Sol-578 (brain penetrant), they're also developing CASC-578 an oral CHK1i.
A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced or Metastatic Solid Tumors:
https://clinicaltrials.gov/study/NCT05983523
Will continue to dig into who may have taken CCT245737 on, but can't shake this tiny nagging fear that some bu@@er has licensed it to shelve it for their own ends.... Pharma is a duplicitous, deceitful business at times.
ATB all genuine holders & posters.
Basically they have a claim of a PASI75 score after 12 weeks. Pretty certain 1801 can achieve that if not better it.
Deucravacitinib 1st in class is now looking to become not best in class and 4 billion was paid up front.
Good informative pertinent postings from C79 as usual.
Regards
Most of us expect news soon, so hopefully this SP will be a bad dream in the near future. GLA
I didn't believe £1 was possible, not so long ago.
This cant go below 30p can it, really........................................
Be interested to read the six monthly report
which is due to be published anytime
Given the share price collapse in the same period it will be interesting to receive the BoD comments
D:
All 34.9 are buys as I topped up earlier although still not showing
Morning SOG - whilst Sierra might appear to be a good candidate there must be lots of other private companies, each protected from public view by the pharma's that own them. If any trial under control of the subsidiary fails then it's at arm's length of the parent company and won't create such large headlines.
It does make you wonder who was in the orderly queue - only small biotechs or did one or two of the majors also take an interest?
Someone attending the next meeting should pump the BoD for off-the-record info to be shared freely here!
Interesting post HbD.
I don't think you are way out with Sierra Oncology. However, it may well be that former directors or CEO's may have an involvement somewhere along the lines of perhaps a new private company. Nick Glover l have spoken about with MEI Pharmaceuticals but also Mark Kowalski who was Chief Medical Officer.
Stephen Dilley was CEO of Sierra during end development of Momoletonib and the sale of SO to GSK prior to commercialisation.
Shareholders were up in arms at the price of 1.9 billuon for SO. GSK stated that their main objective was for the Momoletonib.
No value had been attributed to 737. Edison had put a value of around 120 million dollars on the then current worth of 737 with a 1 in 6 chance if success. This equates to around 720 million worth if success was gained with the current 737 and LDG combo plus substantial preclinical work but not exhaustive in combination therapy with other inhibitors. This value was also placed prior to gaining patent protections granted on 2020.
Stephen Dilley resigned in 2022 after the takeover of SO by GSK. He was paid a years salary along with other benefits making circa 1.4 million dollars in total.
Why did he resign?
Of he were sacked he would lose these benefits unless an appeal involving legal proceedings would take place. Thete would have to be reason for SO to seek to dismiss him. This would also expose other persons involved in the reasonings for SO dismissal.
Shareholders up in arms, seeking blood.
I am very much of the firm belief that informal discussions had been taking place since 2020 between GSK and formal discussions commenced very late 2021.
Now GSK had met their main objective of obtaining Momoletonib for commercialisation.
What was the non main objective? My opinion of this is since early non formal communications from 2020 that in addition to the probable success of trial data of Momo that 737 was also discussed and that it was in the interest of GSK that 737 was not pursued. Indeed the for sale sign for 737 came down around Easter 2020.
Nothing has been done with 737 since and yet does have a value in addition to significant potential in the treatment of high grade serious ovarian cancer which is in an area of high unmet need.
The recently acquired Tesaro pipeline by GSK for 5.1 billion dollars was already at point of commercialisation and in clinical use. It was also granted clinical use in the EU for HGSOC although at a later period under the watchful eye of the EU safety standards as adverse effects arising warranted observation and restrictions were in place. It is not beyond reasonable comprehension that GSK would not wish to have a competitor in this area with projected sales of over 2 billion a year forecast.
When billions if dollar are involved many means to establish targets by fair means or foul will arise.
In the right hands 737 will be a success as opposed to have the clock run down on a potential beneficial treatmen